Mazdutide: The "Dual Metabolic Engine" Protocol
Disclaimer: This article is for educational and research purposes only. Mazdutide is a dual GLP-1/Glucagon receptor agonist currently under clinical investigation (marketed in China as Xinermei). It is not FDA-approved for unapproved uses in the United States. Information reflects 2025/2026 Phase 3 clinical trial data.
What is Mazdutide?
Mazdutide (formerly IBI362) represents the next generation of metabolic research, often called a "Dual Metabolic Engine." While standard peptides like Semaglutide target only the GLP-1 receptor, Mazdutide is a mammalian oxyntomodulin (OXM) analogue that targets both GLP-1 and the Glucagon Receptor (GCGR).
- GLP-1 Action: Reduces appetite, slows gastric emptying, and improves insulin secretion.
- Glucagon Action: Increases energy expenditure (thermogenesis) and directly improves hepatic (liver) fat metabolism.
- Molecular Focus: Engineered for once-weekly administration with a potent effect on visceral and liver fat.
Current Research Landscape (2025–2026)
Key Study Findings
| Study | Primary Outcome | Reference |
| GLORY-1 (Phase 3) | 14–15% placebo-corrected weight loss at 48 weeks (6mg dose). | Nature (Dec 2025) |
| GLORY-2 (Phase 3) | 20.1% mean weight reduction at 60 weeks (9mg dose). | NEJM / Innovent (2025) |
| Liver Fat Study | ~71.9% reduction in liver fat content via MRI-PDFF. | ObesityWeek (Nov 2025) |
Research Protocols (100mg Vial)
A 100 mg vial is an extremely high-capacity reservoir. Because Mazdutide doses are typically between 3 mg and 9 mg per week, a 100 mg vial can provide research material for several months.
Reconstitution (5 mL BAC Water)
Note: Due to the high amount of peptide powder (100mg), using 5 mL of Bacteriostatic Water is recommended to ensure the solution is not too viscous.
Total Vial: 100 mg (100,000 mcg)
Concentration: 20 mg per 1 mL (200 mcg per unit)
Titration & Weekly Dosing Table
Researchers must follow a strict escalation to allow the Glucagon receptors to adapt without causing excessive tachycardia (elevated heart rate).
| Phase | Weekly Dose | Syringe Units (IU) | Duration |
| Initiation | 1.5 mg | 7.5 Units | Weeks 1–4 |
| Escalation 1 | 3.0 mg | 15 Units | Weeks 5–8 |
| Escalation 2 | 4.5 mg | 22.5 Units | Weeks 9–12 |
| Standard High | 6.0 mg | 30 Units | Weeks 13–16 |
| Max Research | 9.0 mg | 45 Units | Week 17+ |
Frequently Asked Questions
How does Mazdutide differ from Tirzepatide (Mounjaro)?
While Tirzepatide targets GLP-1 and GIP (the "sugar" receptors), Mazdutide targets GLP-1 and Glucagon (the "fat-burning" receptor). The addition of Glucagon increases metabolic rate, whereas GIP primarily focuses on insulin sensitivity and lipid storage.
What is the "Glucagon Effect"?
Because Mazdutide activates the glucagon receptor, it can slightly increase the resting heart rate (typically 2–8 bpm). It also has a profound effect on uric acid reduction, which is a unique benefit not seen as strongly in other GLP-1s.
Is it effective for Fatty Liver (MASLD/MASH)?
Yes. 2025 data showed that 70% of participants achieved normal liver fat levels after 48 weeks. This makes it a primary candidate for research focusing on metabolic-associated steatohepatitic liver disease.
Stability of the 100mg Vial?
A 100 mg vial at a 6 mg/week dose would last over 16 weeks. However, for maximum safety and to prevent bacterial growth or peptide degradation, it is recommended to use the vial within 60 days after the first puncture, even if stored in the refrigerator.
References
- Nature (2025). "Two Phase 3 Clinical Results of Mazdutide in Chinese Adults with Type 2 Diabetes."
- PR Newswire (Feb 2026). "Mazdutide Demonstrates Significant Weight Loss and Metabolic Benefits in Adolescent Trials."
- World Journal of Pharmacology (Jan 2026). "Mazdutide: An emerging glucagon/GLP-1 dual receptor agonist for obesity."